{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:50:08Z","timestamp":1753876208023,"version":"3.41.2"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Several proton pump inhibitor (PPI) dosing regimens that vary by strength and frequency (once [Qday] or twice [BID] daily) are available to treat gastroesophageal reflux disease (GERD). We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the impact of various PPI regimens on esophageal healing and GERD and heartburn symptoms. To identify relevant studies, we searched EMBASE and PubMed in January 2023, which yielded 1381 records. Eligible RCTs included those that enrolled adults diagnosed with GERD and compared different dosing regimens within the same PPI. The outcomes were esophageal healing and resolution of GERD and heartburn symptoms within 12\u00a0weeks (i.e. short-term) and\u2009&amp;gt;\u200912\u00a0weeks (i.e. long-term). Meta-analysis pooling of the odds ratios with 95% confidence intervals were estimated using the random-effects inverse-variance model. Overall, a total of 38 RCTs across 20 countries (N\u2009=\u200915,540 patients, mean age 50\u00a0years, 55% male) were included. Most PPI trials compared half standard dose Qday versus standard dose Qday or standard dose Qday versus double standard dose Qday. In general, when considering daily dosing, higher PPI strength significantly improved esophageal healing and relief of GERD symptoms both in the short- and long-term. Fewer trials compared Qday versus BID dosing; the impact of BID dosing on outcomes was inconsistent across the different PPI strength comparisons. In conclusion, this meta-analysis revealed that increasing PPI Qday dosages led to improved GERD outcomes. However, few studies compared Qday to BID dosing; as twice daily PPI usage is common in clinical practice, further studies are warranted to determine whether such dosing improves clinical outcomes.<\/jats:p>","DOI":"10.1093\/dote\/doae109","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T10:31:34Z","timestamp":1734172294000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparing the efficacy of different proton pump inhibitor dosing regimens for the treatment of gastroesophageal reflux disease: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"38","author":[{"given":"Tyra","family":"Nguyen","sequence":"first","affiliation":[{"name":"Division of Population Sciences, Department of Biomedical Sciences, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Barnhill","sequence":"additional","affiliation":[{"name":"Division of Population Sciences, Department of Biomedical Sciences, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Zhornitskiy","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Department of Medicine , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Sang","family":"Yu","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Department of Medicine , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garth","family":"Fuller","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Department of Medicine , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Makaroff","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Department of Medicine , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan M R","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Department of Medicine , Los Angeles, CA ,","place":["USA"]},{"name":"Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Gresham","sequence":"additional","affiliation":[{"name":"Division of Population Sciences, Department of Biomedical Sciences, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-9479","authenticated-orcid":false,"given":"Christopher V","family":"Almario","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Department of Medicine , Los Angeles, CA ,","place":["USA"]},{"name":"Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"issue":"8","key":"2025010911473871900_ref1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2025010911473871900_ref2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","article-title":"Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"63","author":"El-Serag","year":"2014","journal-title":"Gut"},{"key":"2025010911473871900_ref3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2019.12.014","article-title":"Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms","volume":"158","author":"Delshad","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"2025010911473871900_ref4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MCG.0b013e31815ea27b","article-title":"Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study","volume":"43","author":"Eslick","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"3 Suppl","key":"2025010911473871900_ref5","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0002-9270(03)00010-8","article-title":"The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease","volume":"98","author":"Ofman","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2025010911473871900_ref6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0002-9343(97)00354-9","article-title":"The impact of gastroesophageal reflux disease on health-related quality of life","volume":"104","author":"Revicki","year":"1998","journal-title":"Am J Med"},{"issue":"3","key":"2025010911473871900_ref7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0002-9343(97)00354-9","article-title":"The impact of gastroesophageal reflux disease on health-related quality of life","volume":"104","author":"Wood","year":"1998","journal-title":"Am J Med"},{"issue":"1","key":"2025010911473871900_ref8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018","volume":"156","author":"Peery","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"2025010911473871900_ref9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and Management of Gastroesophageal Reflux Disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref10","doi-asserted-by":"crossref","first-page":"9865963","DOI":"10.1155\/2017\/9865963","article-title":"A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of gastroesophageal reflux disease","volume":"2017","author":"Zhang","year":"2017","journal-title":"Gastroenterol Res Pract"},{"issue":"8","key":"2025010911473871900_ref11","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1185\/03007990903035745","article-title":"Treatment patterns and symptom control in patients with GERD: US community-based survey","volume":"25","author":"Chey","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2025010911473871900_ref12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","article-title":"American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease","volume":"135","author":"Kahrilas","year":"2008","journal-title":"Gastroenterology"},{"key":"2025010911473871900_ref13"},{"key":"2025010911473871900_ref14"},{"key":"2025010911473871900_ref15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/bmj.318.7182.502","article-title":"Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European study group","volume":"318","author":"Bardhan","year":"1999","journal-title":"BMJ"},{"key":"2025010911473871900_ref16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.36.4.492","article-title":"Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo investigator group","volume":"36","author":"Bate","year":"1995","journal-title":"Gut"},{"key":"2025010911473871900_ref17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00042737-200012080-00008","article-title":"Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole study group","volume":"12","author":"Birbara","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025010911473871900_ref18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1365-2036.2004.02233.x","article-title":"Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis","volume":"20","author":"Bochenek","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2036.2005.02555.x","article-title":"Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States","volume":"22","author":"Caos","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref20","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1111\/j.1572-0241.2000.03179.x","article-title":"Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease","volume":"95","author":"Caos","year":"2000","journal-title":"Rebeprazole Study Group Am J Gastroenterol"},{"key":"2025010911473871900_ref21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-199802000-00004","article-title":"Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD study group","volume":"10","author":"Carlsson","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025010911473871900_ref22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/ajg.2009.632","article-title":"Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades a and B","volume":"105","author":"Chen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref23","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1023\/A:1018822532736","article-title":"Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole study group","volume":"43","author":"Cloud","year":"1998","journal-title":"Dig Dis Sci"},{"key":"2025010911473871900_ref24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/003655200453566","article-title":"Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease","volume":"35","author":"Delchier","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"2025010911473871900_ref25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1572-0241.1998.00238.x","article-title":"A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis","volume":"93","author":"Earnest","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1365-2036.2009.03948.x","article-title":"Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg","volume":"29","author":"Eggleston","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref27","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2036.2009.04013.x","article-title":"Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease","volume":"29","author":"Fass","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1365-2036.1997.00185.x","article-title":"Treating the symptoms of gastro-oesophageal reflux disease: a double- blind comparison of omeprazole and cisapride","volume":"11","author":"Galmiche","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0016-5085(94)90531-2","article-title":"Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian clinics for united research group","volume":"107","author":"Hallerb\u00e4ck","year":"1994","journal-title":"Gastroenterology"},{"key":"2025010911473871900_ref30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2036.1997.144320000.x","article-title":"Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis","volume":"11","author":"Hatlebakk","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1365-2036.1997.00246.x","article-title":"Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole","volume":"11","author":"Hatlebakk","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","article-title":"Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"96","author":"Johnson","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref33","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1572-0241.2005.00285.x","article-title":"Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial","volume":"100","author":"Johnson","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref34","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The esomeprazole study investigators","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ajg.2012.19","article-title":"Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study","volume":"107","author":"Kinoshita","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref36","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00535-017-1417-z","article-title":"Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study","volume":"53","author":"Kinoshita","year":"2018","journal-title":"J Gastroenterol"},{"key":"2025010911473871900_ref37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3109\/00365529509101589","article-title":"Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study","volume":"30","author":"Laursen","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"2025010911473871900_ref38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3109\/00365529709011212","article-title":"Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response","volume":"32","author":"Lind","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"2025010911473871900_ref39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2036.2003.01410.x","article-title":"Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis","volume":"17","author":"Metz","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref40","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","article-title":"Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial","volume":"97","author":"Miner","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0004-28032002000200010","article-title":"Assessment of effectiveness of different dosage regimens of pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis","volume":"39","author":"Moretzsohn","year":"2002","journal-title":"Arq Gastroenterol"},{"key":"2025010911473871900_ref42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CEG.S12333","article-title":"Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease","volume":"3","author":"Orlando","year":"2010","journal-title":"Clin Exp Gastroenterol"},{"key":"2025010911473871900_ref43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2009.04064.x","article-title":"Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects","volume":"30","author":"Peura","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00042737-200012040-00010","article-title":"Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease","volume":"12","author":"Plein","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025010911473871900_ref45","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2000.03254.x","article-title":"Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD study group","volume":"95","author":"Richter","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2025010911473871900_ref46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2036.2004.02121.x","article-title":"Prevention of erosive oesophagitis relapse with pantoprazole","volume":"20","author":"Richter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref47","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1001\/archinte.160.12.1810","article-title":"Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis","volume":"160","author":"Richter","year":"2000","journal-title":"Arch Intern Med"},{"key":"2025010911473871900_ref48","doi-asserted-by":"crossref","first-page":"859","DOI":"10.7326\/0003-4819-124-10-199605150-00001","article-title":"Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial","volume":"124","author":"Robinson","year":"1996","journal-title":"Ann Intern Med"},{"key":"2025010911473871900_ref49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0016-5085(92)91790-B","article-title":"Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter study","volume":"102","author":"Sontag","year":"1992","journal-title":"Gastroenterology"},{"key":"2025010911473871900_ref50","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00535-008-2214-5","article-title":"Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease","volume":"43","author":"Uemura","year":"2008","journal-title":"J Gastroenterol"},{"key":"2025010911473871900_ref51","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1046\/j.1365-2036.2001.01024.x","article-title":"The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"15","author":"Vakil","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"2025010911473871900_ref52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2036.2004.01846.x","article-title":"Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease","volume":"19","author":"Wong","year":"2004","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/1\/doae109\/60927400\/doae109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/1\/doae109\/60927400\/doae109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:48:09Z","timestamp":1736423289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doae109\/7914367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doae109","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"type":"print","value":"1120-8694"},{"type":"electronic","value":"1442-2050"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,1]]},"article-number":"doae109"}}